SEC Company Response from PhaseBio Pharmaceuticals Inc (PHASQ) (CIK 0001169245) — Jan 6, 2020
PhaseBio Pharmaceuticals Inc (PHASQ) (CIK 0001169245)
Date: Jan. 6, 2020 · CIK: 0001169245 · Accession: 0001193125-20-002161
AI Filing Summary & Sentiment
File numbers found in text: 333-235735
Letter
PHASEBIO PHARMACEUTICALS, INC.
11260 El Camino Real, Suite 100
San Diego, CA 92130
January 6, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Paul Fischer
RE: PhaseBio Pharmaceuticals, Inc.
Registration Statement on Form S-3
File No. 333-235735
Acceleration Request
Requested Date:
January 8, 2020
Requested Time:
4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) to become effective on January 8, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Madison Jones, counsel to the Registrant, at (202) 728-7087.
Very truly yours,
PhaseBio Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm CORRESP PHASEBIO PHARMACEUTICALS, INC. 11260 El Camino Real, Suite 100 San Diego, CA 92130 January 6, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Paul Fischer RE: PhaseBio Pharmaceuticals, Inc. Registration Statement on Form S-3 File No. 333-235735 Acceleration Request Requested Date: January 8, 2020 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) to become effective on January 8, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable. Once the Registration Statement has been declared effective, please orally confirm that event with Madison Jones, counsel to the Registrant, at (202) 728-7087. Very truly yours, PhaseBio Pharmaceuticals, Inc. /s/ John Sharp John Sharp Chief Financial Officer cc: Jonathan P. Mow, Chief Executive Officer Kris Hanson, Vice President, Head of Legal Christian E. Plaza, Cooley LLP Darren K. DeStefano, Cooley LLP